© 2021 - Negotiamini. All Rights Reserved.
AUSTIN, Texas, May 6, 2021 /PRNewswire/ — Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE ), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced the launch of THINK ARGININE, a disease education initiative focused on improving the awareness and diagnosis of Arginase 1 Deficiency (ARG1–D), a devastating and progressive rare metabolic disease. People living with ARG1-D are faced with debilitating, progressive disease manifestations that create significant challenges in daily life, including mobility issues, intellectual disability, developmental delays and seizures. Think Arginine logo The THINK ARGININE campaign consists of a comprehensive program to educate healthcare providers on when to suspect ARG1-D, the significance of persistently high levels of arginine as the driver of the disease, and the benefits of early diagnosis. In order to support healthcare providers in making diagnoses, THINK ARGININE also includes no-charge diagnostic testing for adults and children with suspected ARG1-D. The diagnostic testing program includes amino acid testing working with Mayo Clinic Laboratories and genetic testing partnered with Invitae.
“Like many rare diseases, patients with ARG1-D frequently experience a frustrating and prolonged diagnostic journey before receiving the correct diagnosis. The uncertainties introduced by the challenges in getting […]